The Valley Desk

NCT04640623 · Interventional trial

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Overall registry status Active not recruiting

Phase 2

Conditions Urinary Bladder Neoplasms

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov